Reteplase appears to be another safe and effective thrombolytic option for the treatment of acute ischemic stroke, according to results from the randomized RAISE trial. When given within the first 4.5 ...

A new trial has found the thrombolytic reteplase to be superior to alteplase in patients with acute ischemic stroke presenting within 4.5 hours of symptom onset, with an excellent functional outcome ...

Please provide your email address to receive an email when new articles are posted on . Reteplase was superior to alteplase at reducing disability after acute ischemic stroke. Mortality was similar ...

Reteplase more likely to result in excellent functional outcome than alteplase for ischemic stroke within 4.5 hours of symptom onset. HealthDay News — Reteplase is noninferior to alteplase for ...

Please provide your email address to receive an email when new articles are posted on . In a phase 2 study, reteplase demonstrated similar efficacy and safety vs. alteplase for the treatment of acute ...

"Since the final infarct size was similar between the two groups, there was no benefit on the basis of clinical events, and there was a suggestion of more clinical complications in the combination ...

HALLE, Germany--(BUSINESS WIRE)--Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply ...

HALLE, Germany--(BUSINESS WIRE)-- Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply ...